The increasing dominance of diabetes and its complications has leads to search for natural antidiabetic and antiglycating compounds to control the harmful complications of advanced glycation end-products (AGEs). Natural products offer various therapeutic potentials over synthetic inhibitors, such as low toxicity and diverse biological activities. Ferula asafoetida Linn resin and Eucalyptus globulus Labill leaf oil were chosen based on traditional medical knowledge and scientific data demonstrating their bioactive components and pharmacological value in associated therapeutic applications. This study evaluates the therapeutic potential of F. asafoetida resin and E. globulus leaf oil as antiglycating co-relating phytochemical, antioxidant and antiglycation tests. The oleo-gum resin of F. asafoetida was extracted with distilled water using Soxhlet extraction, whereas E. globulus leaf oil was diluted using methanol in 1:10 ratio for analysis. The total phenolic and flavonoid contents was evaluated using Folin-Ciocalteu and aluminium chloride assays respectively and further GC-MS is used for phytochemical identification. The antioxidant activity was determined using (2,2-diphenyl-1-picrylhydrazyl) DPPH, (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) ABTS, nitric oxide scavenging tests and Ferri Reducing Antioxidant Power (FRAP). The antiglycation potential was determined by measuring fructosamine, protein carbonyl concentration, protein aggregation and AGEs formation. E. globulus oil exhibited higher phenolic and flavonoid content and antioxidant activity (p < 0.05), while F. asafoetida resin extract inhibited glycation intermediates and AGEs (p < 0.05). These findings point to their potential use in natural therapeutic formulations for diabetes-related oxidative and glycaemic stress.